KRAS and neoplasm: In addition to targeting epigenetic regulation and tumor metabolism, therapies targeting oncogenes can also effectively inhibit multiple pathways associated with tumor cells, leading to decreased viability or death of tumor cells, such as those targeting KRAS [233], EGFR [234, 235], and HER2 [234]; targeting cell cycle-related genes, such as CDKs, PLK, WEE1, Aurora A, and CHK1/2 [236], can also effectively prevent mitosis in tumor cells and reduce their proliferative activity.